Dermorphin vs PEA
A side-by-side research comparison of Dermorphin and PEA across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dermorphin | PEA |
|---|---|---|
| Full name | Dermorphin (Opioid Heptapeptide) | Palmitoylethanolamide |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Research compound | Dietary supplement (medical food in EU) |
| Mechanism | Binds mu-opioid receptors with very high affinity and selectivity, producing potent analgesia. Its unusual D-alanine residue makes it resistant to breakdown, contributing to a much stronger effect than morphine on a per-weight basis. | Activates PPARĪ± nuclear receptors for anti-inflammatory gene transcription. Inhibits mast cell degranulation. Enhances endocannabinoid tone by inhibiting FAAH (increasing anandamide). Desensitizes TRPV1 pain channels via allosteric modulation. |
| Molecular weight | 803.9 Da | 299.49 Da |
| Half-life | Short (peptide) | ~1-2 hours (micronized form extends effects) |
| Bioavailability | Injection (research) | ~20% (standard); improved with micronized/ultra-micronized forms |
| Typical dose | Not established for human use | 300-1200 mg |
| Frequency | Research only | 2-3x daily |
| Route | Injection (research) | Oral (micronized preferred) |
Dermorphin reported benefits
- Potent analgesia (research context)
- High mu-opioid receptor selectivity (research interest)
PEA reported benefits
- Chronic pain reduction
- Neuropathic pain relief
- Anti-inflammatory (mast cell stabilization)
- No tolerance or dependence
- Neuroprotection
- Safe with other medications
Related comparisons
Research and educational reference only. Not medical advice.